Propanc Biopharma Provides Corporate Update & Year-End June 30, 2025-26, Financial Results
"The Company is poised to capitalize on the foundation set...with the advancement of PRP to a Phase 1b FIH study in up to 50 patients with solid tumors"
"The Company is poised to capitalize on the foundation set...with the advancement of PRP to a Phase 1b FIH study in up to 50 patients with solid tumors"